-
公开(公告)号：US20180072712A1
公开(公告)日：2018-03-15
申请号：US15818826
申请日：2017-11-21
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Venkatram Reddy Paidi , Sreekantha Ratna Kumar , Abhisek Banerjee , Ramesh Sistla , Satheesh Kesavan Nair , William J. Pitts , John Hynes
IPC: C07D417/14 , C07D487/04 , C07D471/04 , C07D413/14 , C07D417/04 , C07D413/04
CPC classification number: C07D417/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04
Abstract: Compounds having the following formula: or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C—R7, are useful as kinase modulators, including IRAK-4 modulation.
-
2.发明授权公开(公告)号：US09242975B2
公开(公告)日：2016-01-26
申请号：US14371456
申请日：2013-01-11
Applicant: Bristol-Myers Squibb Company
Inventor： Venkatram Reddy Paidi , Sreekantha Ratna Kumar , Abhisek Banerjee , Ramesh Sistla , Satheesh Kesavan Nair , William J. Pitts , John Hynes
IPC: C07D417/14 , C07D413/14 , C07D413/04 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04
CPC classification number: C07D417/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D471/10 , C07D487/04
Abstract: Compounds having the following formula: wherein A is, or; and X is N or C—R7, or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, are useful as kinase modulators, including IRAK-4 modulation.
Abstract translation: 具有下式的化合物：其中A是或; 并且X是N或C-R7，或其对映体，非对映体或其药学上可接受的盐，可用作激酶调节剂，包括IRAK-4调节。
-
公开(公告)号：US20150284382A1
公开(公告)日：2015-10-08
申请号：US14441705
申请日：2013-11-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Rajeev S. Bhide , John V. Duncia , John Hynes , Satheesh K. Nair , William J. Pitts , Sreekantha R. Kumar , Daniel S. Gardner , Natesan Murugesan , Venkatram Reddy Paidi , Joseph B. Santella , Ramesh Sistla , Hong Wu
IPC: C07D417/14 , C07D401/14 , C07D405/12 , C07D405/14 , C07D213/74 , C07D401/12
CPC classification number: C07D407/14 , C07D213/74 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D417/14
Abstract: Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.
Abstract translation: 具有下式（I）的化合物或其立体异构体或其药学上可接受的盐，其中R 2是单环杂芳基，且R 1，R 3，R 4，R 5和R 6如本文所定义，可用作激酶调节剂，包括IRAK -4抑制。
-
公开(公告)号：US09862715B2
公开(公告)日：2018-01-09
申请号：US14960785
申请日：2015-12-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Venkatram Reddy Paidi , Sreekantha Ratna Kumar , Abhisek Banerjee , Ramesh Sistla , Satheesh Kesavan Nair , William J. Pitts , John Hynes
IPC: C07D417/04 , C07D417/14 , C07D413/14 , C07D413/04 , C07D471/04 , C07D487/04
CPC classification number: C07D417/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04
Abstract: Compounds having the following formula: or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C—R7, are useful as kinase modulators, including IRAK-4 modulation.
-
![SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS](/abs-image/US/2016/10/27/US20160311824A1/abs.jpg.150x150.jpg)
5.发明申请SUBSTITUTED 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS CASEIN KINASE 1 D/E INHIBITORS 审中-公开取代4,5,6,7-四氢吡唑并[1,5-A]吡啶衍生物作为CASEIN KINASE 1 D / E抑制剂公开(公告)号：US20160311824A1
公开(公告)日：2016-10-27
申请号：US15034217
申请日：2014-11-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Upender Velaparthi , Chetan Padmakar Dame , Peiying Liu , Mark D Wittman , Bradley C. Pearce , Erika M.V. Araujo , Bireshwar Dasgupta , Jalathi Surendran Nair , Sakthi Kumaran Janakiraman , Chandrasekhar Reddy Rachamreddy , Mallikarjuna Rao Mettu , Arul Mozhi Selvan Subbiah Karuppiah , Bandreddy Subba Reddy , Pulicharla Nagalakshmi , Rajesh Onkardas Bora , Shilpa Holehatti Maheshwarappa , Selvakumar Kumaravel , Dibakar Mullick , Ramesh Sistla
IPC: C07D487/04 , C07D487/20 , C07D491/147 , C07D491/20 , C07D519/00 , C07D487/10
CPC classification number: C07D487/04 , C07D487/10 , C07D487/20 , C07D491/147 , C07D491/20 , C07D519/00
Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
Abstract translation: 及其药学上可接受的盐。 式（I）的化合物抑制蛋白激酶活性，从而使它们用作抗癌剂。
-
Patent Agency Ranking
6.发明授权公开(公告)号：US09273058B2
公开(公告)日：2016-03-01
申请号：US14541343
申请日：2014-11-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Upender Velaparthi , Chetan Padmakar Darne , Peiying Liu , Mark D. Wittman , Bradley C. Pearce , Erika M. V. Araujo , Bireshwar Dasgupta , Jalathi Surendran Nair , Sakthi Kumaran Janakiraman , Chandrasekhar Reddy Rachamreddy , Mettu Mallikarjuna Rao , Arul Mozhi Selvan Subbiah Karuppiah , Bandreddy Subba Reddy , Pulicharla Nagalakshmi , Rajesh Onkardas Bora , Shilpa Holehatti Maheshwarappa , Selvakumar Kumaravel , Dibakar Mullick , Ramesh Sistla
IPC: C07D487/04 , C07D487/10 , C07D487/20 , C07D491/147 , C07D491/20 , A61K31/4985 , A61K31/499 , A61K31/501 , A61K31/506 , A61K31/5377 , A61P19/02
CPC classification number: C07D487/04 , C07D487/10 , C07D487/20 , C07D491/147 , C07D491/20 , C07D519/00
Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐。 式（I）的化合物抑制蛋白激酶活性，从而使它们用作抗癌剂。
-
7.发明授权Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors 有权可用作激酶抑制剂的噻唑基或噻二唑基取代的吡啶基化合物公开(公告)号：US09242976B2
公开(公告)日：2016-01-26
申请号：US14371463
申请日：2013-01-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Venkatram Reddy Paidi , Sreekantha Ratna Kumar , Abhisek Banerjee , Ramesh Sistla , Satheesh Kesavan Nair , William J. Pitts , John Hynes
IPC: C07D417/14 , C07D413/14 , C07D413/04 , C07D417/04 , C07D471/04 , C07D487/04
CPC classification number: C07D417/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04
Abstract: Compounds having the following formula (I) or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C—R7, are useful as kinase modulators, including IRAK-4 modulation.
Abstract translation: 具有下式（I）的化合物或其对映体，非对映异构体或其药学上可接受的盐，其中X为N或C-R7，可用作激酶调节剂，包括IRAK-4调节。
-
8.发明申请THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS 有权作为激酶抑制剂有用的三唑基或噻二唑基取代的吡啶化合物公开(公告)号：US20150018344A1
公开(公告)日：2015-01-15
申请号：US14371463
申请日：2013-01-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Venkatram Reddy Paidi , Sreekantha Ratna Kumar , Abhisek Banerjee , Ramesh Sistla , Satheesh Kesavan Nair , William J. Pitts , John Hynes
IPC: C07D417/14 , C07D417/04
CPC classification number: C07D417/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04
Abstract: Compounds having the following formula (I) or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C—R7, are useful as kinase modulators, including IRAK-4 modulation.
Abstract translation: 具有下式（I）的化合物或其对映体，非对映异构体或其药学上可接受的盐，其中X为N或C-R7，可用作激酶调节剂，包括IRAK-4调节。
-
公开(公告)号：US09657009B2
公开(公告)日：2017-05-23
申请号：US14441705
申请日：2013-11-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Rajeev S. Bhide , John V. Duncia , John Hynes , Satheesh K. Nair , William J. Pitts , Sreekantha R. Kumar , Daniel S. Gardner , Natesan Murugesan , Venkatram Reddy Paidi , Joseph B. Santella , Ramesh Sistla , Hong Wu
IPC: C07D213/74 , C07D417/14 , C07D401/14 , C07D401/12 , C07D407/14 , C07D405/12 , C07D405/14
CPC classification number: C07D407/14 , C07D213/74 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D417/14
Abstract: Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.
-
10.发明申请THIAZOLYL- OR THIADIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS 审中-公开用作激酶抑制剂的噻唑啉酮或噻二唑基取代的吡啶化合物公开(公告)号：US20160083375A1
公开(公告)日：2016-03-24
申请号：US14960785
申请日：2015-12-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： VENKATRAM REDDY PAIDI , Sreekantha Ratna Kumar , Abhisek Banerjee , Ramesh Sistla , Satheesh Kesavan Nair , William J. Pitts , John Hynes
IPC: C07D417/14
CPC classification number: C07D417/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04
Abstract: Compounds having the following formula: or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C—R7, are useful as kinase modulators, including IRAK-4 modulation.
Abstract translation: 具有下式的化合物或其对映体，非对映异构体或其药学上可接受的盐，其中X为N或C-R7，可用作激酶调节剂，包括IRAK-4调节。
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.03 seconds)
